Citations

Clear

187 citation(s) found for "Ha, Gavin".

Arthroscopic Hip Labral Reconstruction and Augmentation—Retro TAPT: Retrograde Passage, Tie Anterior to Posterior, and Truncate
Cabarcas, Brandon C. , Reuter, Zachary C. , Ina, Jason , Krych, Aaron J. , Hevesi, Mario , Cabarcas, Brandon , Krych, Aaron J , Hevesi, Mario , Ina, Jason G , Ward, Gavin H.

Mayo Clinic

Arthroscopy Techniques | March 14, 2025 | Volume: 14 | Issue: 6 | Pages: No page available

10.1016/j.eats.2025.103514 | PMID 40656683 Get It

Abstract The standard of care for hip labral tears is arthroscopic repair, with labral reconstruction performed more commonly for irreparable tears in order to avoid isolated labral debridement. However, labral reconstruction can be technically demanding. We provide a concise step‐by‐step guide for performing labral reconstruction or augmentation using a modified retrograde pull‐through technique, including tips, tricks, and surgeon pearls, and pitfalls. Despite the procedure's technically challenging nature, we believe our technique highlights several important steps to improve the practicality and efficiency of the case and produce satisfactory patient outcomes. Technique Video video See video under supplementary data.
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Zarif, Talal El , Denu, Ryan , Abdel‐Wahab, Noha , Freeman, Dory , Hayeck, Salim, Anderson, Élizabeth , Goodman, Rachel , Johnson, Douglas B. , Grynberg, Shirly , Shapira, Ronnie, Kwan, Jennifer M. , Long, Georgina V. , Haykal, Tarek , Kojima, Yuki , Yonemor, Kan, Trevino, Alexandra , Hui, Gavin , Drakaki, Alexandra, El‐Am, Edward , Al‐Hader, Ahmad, Babu, P. Narendra , Li, Mingjia , Jones, N. , Herrera, M., Foderaro, Simone , Kim, Chul , Sackstein, Paul , Desai, Aakash , Smith, Caleb J. , Korolewicz, James , Lopetegui‐Lia, Nerea , Funchain, Pauline , Choudhary, Arrush, Asnani, Aarti , Stukalin, Igor , Gallegos, Jesús Antonio Ocejo , Nusrat, Sanober , Malvar, Carmel, McKay, Rana R. , Neilan, Tomas G. , Naqash, Abdul Rafeh , Baena, Javier , El Zarif, Talal , Goodman, Rachel S , Kim, Chul , Desai, Aakash P , Cortellini, Alessio , Pinato, David J , Navani, Vishal , Ocejo Gallegos, Jesus Antonio , Funchain, Pauline , Long, Georgina V , Naqash, Abdul Rafeh , Grynberg, Shirly , Espinar, Javier Baena , Alaiwi, Sarah Abou , Macaron, Walid , Vasbinder, Alexi L. , Woodford, Rachel , Dent, Susan , Kojima, Yuki, Tandon, Ankita, Akhter, Nausheen , Yang, Eric H. , Kozaily, Elie , Farhat, Elias Bou , Mittra, Arjun , Jones, Nicholas, Baena, Javier, Nana, Frank Aboubakar , Parikh, Kaushal , Cortellini, Alessio , Pinato, David J. , Meyers, Daniel E. , Trent, Jonathan C. , Choueiri, Toni K. , Korolewicz, James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 3, 2025 | Volume: 13 | Issue: 3 | Pages: e009364

10.1136/jitc-2024-009364 | PMID 40032601 Get It

Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods This is an international multicenter retrospective study of patients with cancer and cardiac metastasis at baseline. Patients who had received ≥1 dose of ICI were included. Treatment-related adverse events (trAEs) were graded per Common Terminology Criteria for Adverse Event V.5.0. Objective response rates (ORR) were evaluated by Response Evaluation Criteria in Solid Tumors V.1.1 when available. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Results Among 110 pts, median age at ICI initiation was 65 (IQR: 59–75). Median follow-up time since ICI initiation was 36 (95% CI: 26 to 51) months. Melanoma (38%, n=42) and non-small cell lung cancer (24%, n=26) were the most common. 68 (62%) patients received ICIs as first-line, and 29 (26%) patients were treated with combination anti-programmed death-1 and anti-cytotoxic T-lymphocyte antigen 4. The most common location of cardiac metastasis was in the atria (37%, n=41) and ventricles (35%, n=39). 15 patients (13.6%) had bilateral cardiac/pericardial metastasis, 44 (40%) had left-sided, and 43 (39.8%) had right-sided. At ICI initiation, 21% (n=23) had a cardiac thrombus. Cardiology referrals and cardiac MRIs at the time of cancer diagnosis were completed on 58 (53%) and 52 (47%) patients, respectively. Cardiac events occurred in 40 (36%) patients, including arrhythmias (n=14, 13%), arterial/venous emboli (n=4, 3.6%), and cardiac tamponade (n=3, 2.7%). 53 (47%) patients developed trAEs; most common were colitis/diarrhea (n=16, 15%), dermatitis (n=13, 12%), and hepatitis (n=9, 8.2%). ICI-related major cardiac trAEs occurred in 2 (1.8%) patients. 22 patients (20%) developed grade ≥3 trAE. Patients with multiple cardiac metastases had significantly lower responses to ICI-based regimens compared with patients with single cardiac metastasis (11% vs 63%, p=0.02). For melanoma, ORR, median PFS, and median OS were 38%, 9.0 months, and 28.9 months, respectively. 83% of patients with melanoma had concordant responses in overall disease burden and cardiac disease. 91 patients discontinued ICIs, and the main reason was progression or death in 55 (49%) patients. Conclusions Among patients with pre-existing cardiac metastasis, ICIs demonstrated meaningful clinical efficacy with no increase in safety signals. Most patients had concordant responses in the overall disease burden and cardiac mass. Multidisciplinary teams are crucial for the appropriate management of patients with cardiac metastasis.
Cumulative deficits frailty index and relationship status predict survival in multiple myeloma
Abdallah, Nadine , Dizona, Paul, LaPlant, Betsy, Schaeferle, Gavin, Aug, Sarah, Weivoda, Megan , Buadi, Francis K. , Warsame, Rahma , Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Menser, Terri , Weivoda, Megan , Dispenzieri, Angela , Buadi, Francis K , Warsame, Rahma , Cook, Joselle M , Lacy, Martha Q , Gertz, Morie A , Kumar, Shaji K , Kumar, Amanika , Dispenzieri, Angela , Cook, Joselle , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | December 18, 2024 | Volume: 9 | Issue: 5 | Pages: 1137-1146

10.1182/bloodadvances.2024014624 | PMID 39693516 Get It

Abstract Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most are based on clinical trial data sets. There are also limited data on the association between frailty and patient-reported outcomes and on the prognostic value of social determinants of health. This study evaluates the prognostic impact of frailty, based on the cumulative deficit frailty index (FI), and relationship and socioeconomic status (SES) in patients with newly diagnosed MM. This retrospective study included 515 patients with MM seen at Mayo Clinic (Rochester, MN) at diagnosis between 2005 and 2018. The FI was calculated using patient-reported data on activities of daily living and comorbidity data, with items scored as 0, 0.5, or 1, in which 1 indicated a deficit. The FI was calculated by dividing the total score by the number of nonmissing items. Frailty was defined as FI ≥0.15; 61% were nonfrail, and 39% were frail. Frailty and nonmarried/relationship status were associated with higher disease stage, decreased the likelihood of early transplantation, and independently associated with decreased survival. SES was not independently associated with survival. Frail patients reported worse scores for fatigue, pain, and quality of life. Approximately a quarter of patients had a deterioration in frailty status at 3 to 12 months, and <10% had improvement. In conclusion, a cumulative deficit FI was associated with higher symptom burden and decreased survival in a real-world cohort of patients with newly diagnosed MM. Frailty status is dynamic and should be reassessed during treatment. Social support has prognostic value and should be evaluated in clinical practice.
Consensus Recommendations for Studies of Outflow Facility and Intraocular Pressure Regulation Using Ex Vivo Perfusion Approaches
Acott, Ted S. , Fautsch, Michael P. , Mao, Weiming , Huang, Alex S. , Kelley, Mary J. , Aga, Mini , Borrás, Terete, Bovenkamp, Diane E. , Chowdhury, Uttio Roy, Clark, Abbot F. , Dibas, Mohammed, Elliott, Michael H. , Faralli, Jennifer A., Gong, Haiyan , Kaufman, Paul L., Keller, Kate E. , Kuehn, Markus H. , Li, Hoi Lam, Lin, Shan C. , Liu, Yutao , McDonnell, Fiona , McDowell, Colleen M. , Mzyk, Philip , Nair, K. Saidas , Overby, Darryl R. , Peters, Donna M. , Raghunathan, VijayKrishna, Rao, Ponugoti Vasantha , Roddy, Gavin W. , Sharif, Najam A. , Shim, Myoung Sup , Sun, Yang , Thomson, Benjamin R. , Willoughby, Colin E. , Freddo, Thomas F., Fuchshofer, Rudolf , Hill, Kamisha R. , Karimi, Alireza , Kizhatil, Krishnakumar , Kopcyznski, Casey C., Patel, Gaurang , Pattabiraman, Padmanabhan P. , Prasanna, Ganesh , Samples, E. Griffen, Samples, John R., Steel, Cynthia, Subramanian, Preeti, Sugali, Chenna Kesavulu , Sherwood, Joseph M. , Wong, Cydney A. , Zode, Gulab , White, Elizabeth , Liu, Yutao , Ethier, C. Ross , Bhattacharya, Sanjoy K. , Du, Yiqin , Herberg, Samuel , Johnstone, Murray , Kelly, Ruth A. , Križaj, David , Lieberman, Raquel L. , McLellan, Gillian J. , Raghunathan, VijayKrishna, Rao, Ponugoti Vasantha , Toris, Carol B. , Zhang, Hao F. , Liton, Paloma B. , Peng, Michael , Reina‐Torres, Ester , Strohmaier, Clemens , Youngblood, Hannah A. , Stamer, William Daniel

Mayo Clinic

Investigative Ophthalmology & Visual Science | December 18, 2024 | Volume: 65 | Issue: 14 | Pages: 32

10.1167/iovs.65.14.32 | PMID 39693082 Get It

Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
Abdallah, Nadine , Gupta, Supriya , Elhaj, Mohammed, Bansal, Radhika , Schaeferle, Gavin, Kourelis, Taxiarchis , Warsame, Rahma , Kapoor, Prashant , Hayman, Suzanne R. , Gertz, Morie A., Lin, Yi, Kumar, Shaji, Rees, Matthew J. , Menser, Terri , Cook, Joselle , Gonsalves, Wilson I. , Buadi, Francis K. , Dingli, David , Gertz, Morie A. , Kumar, Shaji

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4695-4695

10.1182/blood-2024-211768 Get It

Background: Multiple Myeloma (MM) is predominantly a disease of older adults. However, older patients vary widely in physiological status and treatment tolerance. The simplified frailty index (Facon 2020) incorporates age, ECOG performance status, and comorbidities (Charleston Comorbidity Index [CCI]) to classify patients as frail or non-frail. While frailty is associated with increased toxicity with conventional systemic therapies, its impact on outcomes of older patients treated with bispecific antibodies (BsAbs) has not been established. Thus, we conducted a retrospective study to evaluate the efficacy and toxicity of BsAbs in older patients based on frailty. Methods: This is a single institution study. We included patients with MM ≥65 years who initiated treatment with a BsAb at Mayo Clinic in Rochester, MN from August, 2018 to January, 2024. Patients who received a BsAb on trial or as standard of care were included. For patients who received 2 different BsAbs at different timepoints, we included the first treatment only. We grouped patients into frail and non-frail based on the simplified frailty index (score ≥2 = frail). We evaluated the overall response (ORR) and ≥very good partial response (VGPR) rates, progression-free (PFS) and overall (OS) survival, early mortality (within 90 days) including early non-relapse mortality (NRM), and toxicities including cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS) and healthcare utilization. P values were insignificant (>0.05) unless otherwise stated. PFS and OS were calculated from the day of BsAb start. Results: A total of 99 patients age 65-89 years were included. The products used were teclistamab (N=43), talquetamab (N=2), and investigational agents (N=54); 67% were ≥70 and 29% were ≥75 years; 39% were female, 95% were non-Hispanic White and 4% were Black/African American. Seventy patients (71%) were considered frail and 29 (29%) were non-frail. At the time of BsAb start, a higher proportion of frail patients had platelets <75 x 10^9/L (30% vs 8%, P=0.04). Otherwise, there was no significant difference between frail and non-frail patients in age (median: 72 vs 70), hemoglobin <8 g/dL (19% vs 12%), absolute neutrophil count <1 x 10^9/L (6% vs 8%), presence of high-risk FISH (70% vs 60%), ISS stage 3 (32% vs 41%), high LDH (58% vs 61%), presence of extramedullary disease (39% vs 25%), serum creatinine ≥2 mg/dL (15% vs 8%), bone marrow plasma cell% (20% in both), triple- (83% vs 90%) and penta-class refractoriness (63% vs 48%), number of prior lines of therapy (median: 6 in both), prior exposure to BCMA-directed therapy (24% vs 21%, P=0.80) and prior autologous stem cell transplant (73% vs 86%). Step-up dosing was used in 81% vs 48% of patients (P=0.001), and treatment was initiated in the outpatient setting in 46% vs 28% (P=0.12) in frail and non-frail patients, respectively. The median follow-up was 1.9 (95%CI: 1.0-2.3) years. There was no significant difference between frail and non-frail patients in ORR (52% vs 62%), ≥VGPR (46% vs 48%), 1-year PFS (36% vs 48%, P=0.26), or 1-year OS (57% vs 61%, P=0.30), respectively. Age and CCI alone were not associated with PFS or OS, but ECOG >1 was associated with decreased PFS (hazard ratio: 3.1, P=0.001) and OS (hazard ratio: 3.1, P<0.001). There was no significant difference between frail vs non-frail patients in grade 3/4 thrombocytopenia (39% vs 17%, P=0.06), grade 3/4 neutropenia (27% vs 35%), total days of hospitalization (median: 8 vs 5, P=0.35), number of unplanned admissions in 6 months (median: 1 in both), or total hospital days for unplanned admissions (1 vs 2 days). There was no significant difference between frail and non-frail patients in early mortality (23% vs 10%, P=0.17), including early NRM (4% in both), CRS (59% vs 66%), grade 3-4 CRS (3% vs 7%), or CRS recurrence (21% vs 10%). ICANS occurred in 5 (9%) frail patients and 1 non-frail patient (grade 2); among frail patients, grades were: 1 in 3 patients, 3 in 1 patient, and 4 in 1 patient. Similarly, there was no significant difference in CRS/ICANS between the 2 groups when patients with and without step-up dosing were analyzed separately. Conclusion: Frailty, defined using the simplified frailty index, was not significantly associated with inferior efficacy or increased toxicity with BsAb therapy among older patients with MM. Poor performance status predicted inferior PFS and OS, while age and comorbidity scores did not.
CSIG-03. MT-125 INHIBITS NON-MUSCLE MYOSIN IIA AND IIB, SYNERGIZES WITH ONCOGENIC KINASE INHIBITORS, AND PROLONGS SURVIVAL IN GLIOBLASTOMA
Rosenfeld, Steven S. , Kenchappa, Rajappa S., Dovas, Athanassios, Haddock, Ashley , Canoll, Peter, Rumbaugh, Gavin , Griffin, Patrick , Miller, Courtney , Radnai, László , Zarco, Natanael , Griffin, Patrick, Kamenecka, Theodore M.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii63-viii64

10.1093/neuonc/noae165.0252 Get It

Abstract We have shown that members of the non-muscle myosin II (NMII) family of molecular motors are non-redundant drivers of both invasion and proliferation in glioblastoma (GBM), consistent with the canonical roles NMII isoforms play in cell motility and cytokinesis. However, we have also found that NMII also has a non-canonical role by regulating oncogenic signaling pathways relevant to GBM pathogenesis. This unexpected finding has led us to identify and characterize MT-125, a highly specific small molecule inhibitor of the two predominant NMII isoforms in GBM (NMIIA and NMIIB), and we have studied its effects in pre-clinical GBM models. MT-125 has high brain penetrance and retention; an excellent safety profile in rodents and canines with no changes in metabolic or hematologic indices after prolonged administration; is well-tolerated with daily dosing for at least 85 consecutive days; blocks GBM invasion and cytokinesis, consistent with the canonical roles of NMII; and prolongs median survival by 35% as a single agent in murine GBM models. MT-125 increases signaling along both the PDGFR- and MAPK-driven pathways through a mechanism that involves the upregulation of reactive oxygen species, leading to oncogene addiction to these pathways. As a consequence, MT-125 is synthetically lethal when combined with FDA-approved, CNS-permeant inhibitors of PDGFR and mTOR in vitro. Combining MT-125 with sunitinib, a PDGFR inhibitor, or paxalisib, a combined PI3 Kinase/mTOR inhibitor, in vivo doubles median survival in a highly aggressive murine orthotopic GBM model. Furthermore, combining MT-125 with sunitinib produces tumor free remissions of >100 days--2.5-fold greater than median survival of either drug alone—in approximately 40% of mice. Our results provide a powerful rationale for developing NMII targeting strategies to treat cancer and demonstrate that MT-125 has strong clinical potential for the treatment of GBM.
Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts
Elliott, Katherine S. , Gilbert, Edmund , Harper, Andrew R. , Sempere, Vicente Peris, Pinto, Anne‐Laurie , Rayner, N. William, Mentzer, Alexander J. , Delanty, Norman, Picard, Géraldine , Titulaer, Maarten J. , Kuhlenbäeumer, Gregor, Mignot, Emmanuel , Cavelleri, Gianpiero L, Irani, Sarosh R. , Cavalleri, Gianpiero L. , Mentzer, Alexander J , Handel, Adam , Melzer, Nico , Lee, Soon-Tae , Leypoldt, Frank , Honnorat, Jérôme , Mignot, Emmanuel , Irani, Sarosh R , Cavalleri, Gianpiero L , Titulaer, Maarten J , Binks, Sophie , Muñiz‐Castrillo, Sergio , Araujo, Tânia Kawasaki de , Brown, Andrew , Chong, Amanda Yoon-Yee , Band, Gavin , Costantino, Félicie , Rogemond, Véronique , Handel, Adam E. , Lee, Soon‐Tae , Honnorat, Jérôme , Knight, Julian Charles

Mayo Clinic

Brain | October 24, 2024 | Volume: 148 | Issue: 3 | Pages: 737-745

10.1093/brain/awae349 | PMID 39454566 Get It

Abstract Encephalitis with antibodies to leucine-rich glioma-inactivated 1 (LGI1-Ab-E) is a common form of autoimmune encephalitis, presenting with seizures and neuropsychiatric changes, predominantly in older males. More than 90% of patients carry the human leukocyte antigen (HLA) class II allele, HLA-DRB1*07:01. However, this is also present in 25% of healthy controls. Therefore, we hypothesized the presence of additional genetic predispositions. In this genome-wide association study and meta-analysis, we studied a discovery cohort of 131 French LGI1-Ab-E and a validation cohort of 126 American, British and Irish LGI1-Ab-E patients, ancestry-matched to 2613 and 2538 European controls, respectively. Outside the known major HLA signal, we found two single nucleotide polymorphisms at genome-wide significance (P < 5 × 10−8), implicating PTPRD, a protein tyrosine phosphatase, and LINC00670, a non-protein coding RNA gene. Meta-analysis defined four additional non-HLA loci, including the protein coding COBL gene. Polygenic risk scores with and without HLA variants proposed a contribution of non-HLA loci. In silico network analyses suggested LGI1 and PTPRD-mediated interactions via the established receptors of LGI1, ADAM22 and ADAM23. Our results identify new genetic loci in LGI1-Ab-E. These findings present opportunities for mechanistic studies and offer potential markers of susceptibility, prognostics and therapeutic responses.
Extracting social support and social isolation information from clinical psychiatry notes: comparing a rule-based natural language processing system and a large language model
Patra, Braja Gopal , Lepow, Lauren , Kumar, Praneet Kasi Reddy Jagadeesh, Vekaria, Veer , Sharma, Mohit , Adekkanattu, Prakash , Fennessy, Brian , Hynes, Gavin, Landi, Isotta , Sánchez-Ruiz, Jorge A. , Ryu, Euijung , Nadkarni, Girish N. , Talati, Ardesheer , Zhang, Yiye , Charney, Alexander W. , Pathak, Jyotishman , Lepow, Lauren A , Sharma, Mohit M , Pathak, Jyotishman , Vekaria, Veer , Patra, Braja G , Sanchez-Ruiz, Jorge A , Biernacka, Joanna M. , Weissman, Myrna M. , Olfson, Mark , Mann, J. John

Mayo Clinic

Journal of the American Medical Informatics Association | October 18, 2024 | Volume: 32 | Issue: 1 | Pages: 218-226

10.1093/jamia/ocae260 | PMID 39423850 Get It

Abstract Objectives Social support (SS) and social isolation (SI) are social determinants of health (SDOH) associated with psychiatric outcomes. In electronic health records (EHRs), individual-level SS/SI is typically documented in narrative clinical notes rather than as structured coded data. Natural language processing (NLP) algorithms can automate the otherwise labor-intensive process of extraction of such information. Materials and Methods Psychiatric encounter notes from Mount Sinai Health System (MSHS, n = 300) and Weill Cornell Medicine (WCM, n = 225) were annotated to create a gold-standard corpus. A rule-based system (RBS) involving lexicons and a large language model (LLM) using FLAN-T5-XL were developed to identify mentions of SS and SI and their subcategories (eg, social network, instrumental support, and loneliness). Results For extracting SS/SI, the RBS obtained higher macroaveraged F1-scores than the LLM at both MSHS (0.89 versus 0.65) and WCM (0.85 versus 0.82). For extracting the subcategories, the RBS also outperformed the LLM at both MSHS (0.90 versus 0.62) and WCM (0.82 versus 0.81). Discussion and Conclusion Unexpectedly, the RBS outperformed the LLMs across all metrics. An intensive review demonstrates that this finding is due to the divergent approach taken by the RBS and LLM. The RBS was designed and refined to follow the same specific rules as the gold-standard annotations. Conversely, the LLM was more inclusive with categorization and conformed to common English-language understanding. Both approaches offer advantages, although additional replication studies are warranted.
Impact of Desmopressin ON HemaToma EXPANsion in Patients Presenting to the Emergency Department on Antiplatelet Therapy: DON'T EXPAND Study
Rech, Megan A. , Brown, Caitlin S. , Slocum, Giles W. , Aggarwal, Deep, Ayad, Michael, Delibert, Samantha, Flack, Tara , Guerrero, Luis, Howington, Gavin T. , Koul, Uttara, Laub, Jessica , Malik, Atul, Maynard, Kaylee , Naylor, Ryan M. , Newell, Joshua S, Dee, Elizabeth , Sarangarm, Preeyaporn , Sheldrake, Amy K., Shogren, Sophie L , Treu, Ciarra N, Vantine, Paul, Woolum, Jordan A. , Rech, Megan A , Gilbert, Brian W. , George, Benjamin P. , Koul, Uttara, Malik, Atul, Panos, Nicholas , Ray, Lance , Dee, Elizabeth, Faine, Brett

Mayo Clinic

No container title available | September 3, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4619324/v1 Get It

Abstract Introduction: Current guidelines state the effectiveness of desmopressin to reduce hematoma expansion in antiplatelet-related intracerebral hemorrhage (ICH) is uncertain. This study sought to determine if desmopressin decreased hematoma expansion in ICH patients on antiplatelet agents. Methods: We conducted a multi-center, retrospective propensity-matched cohort study at 11 US emergency departments (ED) that participate in EMPHARM-NET. Adult patients ≥18 years with a primary diagnosis of spontaneous ICH on antiplatelets prior to admission from January 1, 2017 through May 1, 2021 were included. The primary endpoint was good or excellent hemostatic efficacy within the first 24 hours following ICH between patients that did and did not receive desmopressin. Brain imaging was reviewed using 3D-Slicer by blinded expert physicians. Results: Overall, 1408 patients were evaluated for inclusion. A total of 324 patients were included, of which 13.8% (n=45) received desmopressin and 86.1% (n=279) did not. After propensity matching, 35 patients receive desmopressin compared to 140 controls. Baseline hematoma volume (27.6 mL vs. 2.1 mL) and was significantly higher in the desmopressin group. The primary endpoint of good or excellent hemostatic efficacy was similar between groups (74.3% desmopressin group vs. 85% control group, -10.7% [-28.1% to 6.7%]). There was no difference in secondary outcomes. Conclusion: In this multicenter cohort, patients receiving desmopressin had higher baseline intraparenchymal hematoma volume, and did not appear to result in improved hemostatic efficacy relative to the control group. These results suggest against routine administration of desmopressin for antiplatelet-related ICH, though future study in a randomized trial design is necessary.
Palmar Fibromatosis, Updated Review With Relationship to the A1 Pulley, Trigger Finger, and Presence of the Sonographic Comb Sign
Pepperday, Cody A., Murthy, Naveen S. , McKenzie, Gavin , Murthy, Naveen, McKenzie, Gavin A , Pepperday, Cody A., Kakar, Sanjeev

Mayo Clinic

Journal of Ultrasound in Medicine | August 23, 2024 | Volume: 43 | Issue: 12 | Pages: 2281-2293

10.1002/jum.16560 | PMID 39177333 Get It

ObjectivesUpdated retrospective review of the sonographic appearance of palmar fibromatosis (PF) with evaluation of the utility of the Comb Sign previously described in plantar fibromas. Additional evaluation was conducted on the location relative to the flexor tendon, anatomic proximity of palmar fibromas to the A1 pulley and evaluate any potential association with trigger finger.MethodsMedical record and imaging review was performed from 2017 to 2023, for patients with a new onset ultrasound or clinical diagnosis of PF. Clinical associations and imaging morphology were reviewed including presence of the Comb Sign, fibroma association with the A1 pulley, and fibroma association with trigger finger.ResultsExactly 87 total fibromas in 53 patients were evaluated. The Comb Sign was present in 39% of fibromas, usually seen in transverse plane, more prevalent in multifocal disease and larger fibromas. Most (72%) palmar fibromas were within 1 cm of, contacted, or covered the A1 pulley (P < .001). Lateral extension beyond the flexor tendon axis can be seen (44%). Trigger finger and tenosynovitis were rare. However, volume and SI dimension of fibromas were associated with tenosynovitis (P < .0001) and all nine patients with concomitant trigger finger had fibromas within 1 cm from the A1 pulley.ConclusionsThe Comb Sign can aid in sonographic diagnosis of PF. Lateral extension of fibromas can occur. Most palmar fibromas have a significant intimate association with the A1 pulley, and presence of trigger finger with adjacent palmar fibroma can exist and is important for hand surgeons to know preoperatively.